Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 16 articles PubMed · modèle : gemma4:31b
Résumé
Contexte
Usages traditionnels
Composés actifs
Mécanisme d'action
Preuves cliniques
Aqueous and ethanolic extracts significantly inhibited arthritic development, paw edema, bone erosion, and inflammatory cell infiltration in animal models [PMID:30970284].
Selenium nanoparticles synthesized from D. indica leaf extract exhibited dose-dependent toxicity (IC50 of 43.21 μg/mL) and induced apoptosis in A549 cells [PMID:39558605].
D. indica is part of a polyherbal mixture evaluated for SGLT2 inhibitory effects in type 2 diabetic rats [PMID:36081821].
A purified chitinase from the bulbs acted as a growth inhibitor for Fusarium oxysporum and Rhizoctonia solani in vitro [PMID:16739943].
Synthèse des preuves
Sources PubMed
- 1.PMID: 31181697 (2019) — Drimia indica: A Plant Used in Traditional Medicine and Its Potential for Clinical Uses. · Medicina (Kaunas, Lithuania)
- 2.PMID: 25052711 (2015) — Karyological relationships in Indian species of Drimia based on fluorescent chromosome banding and nuclear DNA amount. · Protoplasma
- 3.PMID: 39410890 (2025) — Integrated Transcriptomics and Metabolomics Studies Reveal Steroid Biosynthesis Pathway and BCL2 Inhibitory Diazo-progesterone of Drimia indica for Conservation and Sustainable Utilization. · Current pharmaceutical biotechnology
- 4.PMID: 26155682 (2015) — Diversity of Drimia indica (Roxb.) Jessop and its relationship to Drimia nagarjunae using phenotypic traits and molecular markers. · Indian journal of experimental biology
- 5.PMID: 39558605